Revenue, 2025

USD 0.99 Billion

Forecast, 2035

USD 7.63 Billion

CAGR, 2026-2035

22.63%

Report Coverage

Asia Pacific

Asia Pacific Cell Therapy Market Trends for 2026

The Asia Pacific cell therapy market size was estimated at USD 0.99 billion in 2025 and is predicted to increase from USD 1.22 billion in 2026 to approximately USD 7.63 billion by 2035, expanding at a CAGR of 22.63% from 2026 to 2035. The increasing chronic disease patient population across the Asia Pacific is increasing the use of cell therapies. Growing clinical trials, investments, R&D activities, and new product launches are also enhancing the market growth.

Key Takeaways

• Asia Pacific cell therapy market to crossed USD 1.22 billion by 2026.
• Market projected at USD 7.63 billion by 2035.
• CAGR of 22.63% expected in between 2026 to 2035.
• The global cell therapy market is projected to grow from US$ 7.21 billion in 2025 to US$ 55.72 billion by 2035, at a CAGR of 22.69%.
• By therapy type, the autologous cell therapy segment held a dominant revenue share of 62% of the market in 2025.
• By therapy type, the allogeneic cell therapy segment held 38% of market share in 2025 and is expected to grow at the fastest CAGR during the forecast period.
• By cell type, the stem cells segment held a dominant revenue share of 41% of the market in 2025.
• By cell type, the NK cells segment held 13% of market share in 2025 and is expected to grow at the fastest CAGR during the forecast period.
• By end user, the hospitals segment held a dominant position in the market with a share of 38% in 2025.
• By end user, the CDMOs segment held 14% of the market in 2025 and is expected to grow at the fastest CAGR during the forecast period.
• By application type, the regenerative medicine segment held a dominant revenue share of 34% of the market in 2025.
• By application type, the personalized medicine segment held 12% of market share in 2025 and is expected to grow at the fastest CAGR during the forecast period.

What is the Asia Pacific Cell Therapy?

The Asia Pacific cell therapy market is driven by growing cancer incidences and a shift towards localized biomanufacturing hubs. The Asia Pacific cell therapy refers to research, manufacturing, and commercialization of cell therapies across the Asia Pacific. These therapies help in modifying or replacing patients' cells to fight against disease and restore normal body function.

AI Technological Shifts in the Market

The use of AI in the Asia Pacific cell therapy market is increasing to accelerate cell therapy development and the identification of suitable targets and biomarkers. It also helps in the development of personalized therapies by offering faster and more accurate genomic data analysis and prediction of treatment outcomes. AI also helps in enhancing manufacturing efficiency, optimizing cell therapies, and ensuring stringent quality control.

What are the Trends & Future Outlook of the Market?

Expanding Industries

The rapid expansion of the biotechnology and pharmaceutical sector is increasing the development of new cell therapies. This expansion is also leading to a rise in collaborations, clinical trials, and outsourcing trends.

CAR-T and Stem Cell Therapies on the Rise

The growing incidences of cancer, cardiovascular diseases, neurological diseases, and orthopaedic conditions are increasing the demand for these CAR-T and stem cell therapies.

Escalating Manufacturing Technologies

With the rapidly expanding cell therapies market in the Asia Pacific, the companies are heavily investing in advanced manufacturing technologies. Improved cell processing, automation, and gene editing technologies are being utilized by the companies.

Quick Facts Table

Segmental Insights

By Therapy Type Insights

The Autologous Cell Therapy Segment Dominated the Market With 62% in 2025

The autologous cell therapy segment held the largest revenue share of 62% of the Asia Pacific cell therapy market in 2025, due to strong adoption of patient-specific therapies, which improved safety outcomes. Rising CAR-T approvals in China and Japan also accelerated commercialization. Expansion of the reimbursement frameworks also supported clinical utilization.

The allogeneic cell therapy segment held the second-largest share of 38% of the market in 2025 and is expected to witness the fastest growth during the forecast period, due to off-the-shelf manufacturing, which lowers production timelines and costs. Biotech firms are also expanding scalable cell banking capabilities. Increasing investment in NK-cell platforms also fuels their rapid growth.

By Cell Type Insights

The Stem Cells Segment Dominated the Market With 41% in 2025

The stem cells segment accounted for the highest revenue share of 41% of the Asia Pacific cell therapy market in 2025, driven by regenerative medicine applications, which continued its expansion across orthopedic and neurological diseases. Growth in government support also enhanced the stem cell clinical trials and translational research. Increased stem cell banking infrastructure also improved their accessibility.

The T cells segment held the second-largest share of 33% of the market in 2025, due to the rapid commercialization of CAR-T products, which strengthens demand across oncology centers. Hospitals are also expanding hematologic cancer treatment capacity. Strong pipeline development also supports sustained adoption.

The NK cells segment held 13% of the Asia Pacific cell therapy market share in 2025 and is expected to show the highest growth during the forecast period, due to their scalable allogeneic treatment opportunities. Companies are also prioritizing next-generation immunotherapy platforms. Improved persistence technologies also enhance their therapeutic potential.

The dendritic cells segment held 8% of the market share in 2025, driven by cancer vaccine development, which supports clinical demand for dendritic cell therapies. Research institutes also increase immunotherapy collaborations, increasing their demand. Personalized treatment approaches also encourage their adoption.

By End User Insights

The Hospitals Segment Dominated the Market With 38% in 2025

The hospitals segment held a major revenue share of 38% of the Asia Pacific cell therapy market in 2025, due to their cell therapy administration and patient management activities. Expansion of oncology departments also increased treatment capacity. Reimbursement support also strengthened institutional adoption.

The specialty clinics segment held the second-largest share of 17% of the market in 2025, as they attract increasing patient volumes. Their outpatient treatment models also improve accessibility. Private investments also support advanced therapy infrastructure.

The academic & research institutes segment held 16% of the Asia Pacific cell therapy market share in 2025, due to their intensified stem cell and immunotherapy research programs. Government grants also stimulate translational innovation. Collaborative clinical trials also enhance commercialization opportunities.

The CDMOs segment held 14% of the market share in 2025 and is expected to expand rapidly during the forecast period, driven by growing outsourcing demand as biotech firms seek cost-efficient production. They are also expanding GMP-compliant facilities across Asia-Pacific. Increasing strategic partnerships also accelerates therapy commercialization.

By Application Insights

The Regenerative Medicine Segment Dominated the Market With 34% in 2025

The regenerative medicine segment contributed the biggest revenue share of 34% of the Asia Pacific cell therapy market in 2025, driven by increased chronic disease burden, which promoted regenerative therapy demand. Stem cell technologies have also improved tissue repair outcomes. Government support also expanded their clinical research programs.

The cancer treatment segment held the second-largest share of 30% of the market in 2025, as the CAR-T and TCR therapies are revolutionizing hematologic cancer treatment. Increasing oncology approvals are also enhancing treatment accessibility. Hospitals invest heavily in immunotherapy infrastructure, promoting their adoption.

The drug discovery & development segment held 13% of the Asia Pacific cell therapy market share in 2025, as its cell-based platforms are improving preclinical testing efficiency. Pharmaceutical firms are expanding personalized screening programs. AI-integrated cell models are also accelerating discovery timelines.

The personalized medicine segment held 12% of the market share in 2025 and is expected to gain the highest share during the forecast period, driven by its precision medicine strategies, which increase the adoption of patient-specific therapies. Genomic integration also enhances therapeutic targeting capabilities. Healthcare systems also prioritize individualized treatment approaches.

Global Cell Therapy Market Growth

The global cell therapy market size was estimated at US$ 7.21 billion in 2025 and is projected to grow to US$ 55.72 billion by 2035, rising at a compound annual growth rate (CAGR) of 22.69% from 2026 to 2035.

Regional Insights

Large Patient Population Boosts Asia Pacific

The Asia Pacific cell therapy market held a significant share in 2025, due to the presence of a large patient population. Rapid expansion of industries, hospitals, and manufacturing capabilities also increased the adoption of cell therapies. Growth in government support, clinical trials, and a rise in health awareness also enhanced the market growth.

China Market Trends

China consists of a large patient population, where the growth in cancer and other chronic diseases has increased the adoption of cell therapies. Availability of affordable manufacturing facilities also increased the outsourcing trends. Expansion of the R&D activities and clinical trials also increased their use.

India Market Trends

Increasing cancer cases in India are promoting the adoption of cell therapies. Expanding industries and healthcare infrastructure are also driving the adoption of these therapies. Increasing investments, government initiatives, and collaborations are also fueling their innovations.

Market Value Chain Analysis

R&D

• The R&D of the Asia Pacific cell therapy focuses on the development of off-the-shelf allogeneic therapies, treatment for solid tumors, and automated manufacturing solutions.
• Key players: Legend Biotech, JW Therapeutics.

Clinical Trials and Regulatory Approvals

• The safety endpoints, long-term efficacy profiles, and manufacturing viability are evaluated in the clinical trials and regulatory approvals of the cell therapy in the Asia Pacific.
• Key players: Legend Biotech, JW Therapeutics.

Patient Support and Services

• The specialized apheresis logistics, localized payment assistant programs, and medical travel assistance are provided in the patient support and services for Asia Pacific cell therapy.
• Key players: Novartis, Gilead Sciences.

Who are the Market Top Vendors and What are Their Offerings?

SWOT Analysis

Strengths

• The targeted and cellular level action of the cell therapies is increasing their adoption across the Asia Pacific.
• They are also used to repair or regenerate damaged tissue or organs.
• They also help in reducing the disease relapses or recurrences.
• Their long-term benefits also increase their use.

Weaknesses

• High cost associated with the treatment acts as the major weakness in the Asia Pacific cell therapy market, limiting its accessibility.
• Lack of skilled personnel and specialized infrastructure also reduces their adoption rates.

Opportunities

• The growing incidences of cancer, autoimmune disease, and other chronic diseases are increasing the demand for cell therapy across the Asia Pacific.
• Expanding healthcare infrastructure is also increasing the adoption of advanced cell therapies.
• Increasing R&D activities are also fueling the development of next-generation therapies.
• Expanding government initiatives are also increasing their accessibility and adoption rates.

Threats

• Large-scale manufacturing challenges and long development time, limit the cell therapy innovations in the Asia Pacific.
• Complex production, regulatory compliance, and storage also reduce their advancements.

What are the Major Recent Developments in the Market?

• In November 2025, NexCAR19, the world’s first humanized CAR-T (Chimeric Antigen Receptor T-cell) therapy, developed by ImmunoACT, was launched in India. This therapy will be used to treat refractory or relapsed B-cell Acute Lymphoblastic Leukaemia and B-cell Non-Hodgkin’s Lymphoma cancers.
• In July 2025, the 3D FloTrix Experience Center was launched in Singapore by CytoNiche Biotech. This launch will also offer the technology used in China’s first-approved stem cell therapy, and will represent a crucial breakthrough in the firm’s expansion plan.

Segments Covered in the Report

By Therapy Type

• Autologous Cell Therapy
  • CAR-T Therapy
  • Stem Cell Therapy
  • TCR-T Therapy
  • Dendritic Cell Therapy
• Allogeneic Cell Therapy
  • Allogeneic CAR-T
  • NK Cell Therapy
  • Mesenchymal Stem Cell Therapy
  • Induced Pluripotent Stem Cell Therapy

By Cell Type

• Stem Cells
  • Hematopoietic Stem Cells
  • Mesenchymal Stem Cells
  • Induced Pluripotent Stem Cells
• T Cells
  • CAR-T Cells
  • TCR-T Cells
• NK Cells
• Dendritic Cells
• Others
  • Macrophages
  • Fibroblasts

By Therapeutic Area

• Oncology
  • Hematological Malignancies
  • Solid Tumors
• Musculoskeletal Disorders
• Cardiovascular Diseases
• Neurological Disorders
• Autoimmune Diseases
• Dermatology
• Others
  • Ophthalmology
  • Rare Genetic Disorders

By Technology

• Viral Vector-Based Therapy
  • Lentiviral Vectors
  • Retroviral Vectors
  • Adenoviral Vectors
• Non-Viral Gene Delivery
  • Electroporation
  • Lipid Nanoparticles
  • CRISPR-based Editing
• Genome Editing Technologies
  • CRISPR-Cas9
  • TALEN
  • Zinc Finger Nucleases

By Source

• Bone Marrow
• Adipose Tissue
• Umbilical Cord Blood
• Peripheral Blood
• Others
  • Placental Tissue
  • Dental Pulp

By End User

• Hospitals
• Specialty Clinics
• Academic & Research Institutes
• Cell Therapy Manufacturing Centers
• Contract Development & Manufacturing Organizations (CDMOs)

By Application

• Regenerative Medicine
• Cancer Treatment
• Drug Discovery & Development
• Tissue Engineering
• Personalized Medicine

By Region

• Asia Pacific
  • China
  • Taiwan
  • India
  • Japan
  • Australia and New Zealand
  • ASEAN Countries (Singapore, Malaysia)
  • South Korea
  • Rest of APAC